Stealthy Atia Medical said it raised $5 million in a Series B round, with the 1st $3 million tranche coming from Medvance Incubator Partners.
Atia Medical is a portfolio company of Campbell, Calif.-based medical device incubator Shifamed, which formed early-stage medtech venture fund Medvance with partner Delos Capital, according to a press release.*
"We are grateful for Medvance Incubator Partners’ support so that we may remain focused on product development," Atia Medical CEO Mariam Maghribi said in prepared remarks.
Although the company is tight-lipped about its technology, in August 2014 Shifamed applied for a U.S. patent for a hydrophilic "accommodating" intraocular lens. The device is comprised of 2 lenses and an adhesive portion between the lenses that forms a fluid chamber, according to the patent.
Shifamed’s application for the Atia trademark listed the development of intraocular lenses as its "goods & services" area.
And Claudio Argento, listed as an inventor on the patent, is a member of Shifamed’s research & development team, according to Shifamed’s website. Argento was previously a senior director of R&D at PowerVision Lens, where he lead in the development of an accommodating intraocular lens. Argento’s previous work included a system for delivery of intraocular lenses into an eye, filed with PowerVision and approved in February.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.